Uso de recursos durante la hospitalización y un año tras el alta en pacientes críticos con COVID-19 supervivientes a la primera ola de la pandemia. Estudio NUTRICOVID
The study describes the use of resources associated with COVID-19 in intensive care unit patients who survived the first wave of the pandemic during their hospitalisation and one year after discharge.
Long-term nutritional, functional status and health-related quality of life of critically ill COVID-19 survivors: one-year follow-up of NUTRICOVID study
This work aimed to show nutritional, functional and health-related quality of life outcomes in critically ill patients surviving COVID-19 one year after hospital discharge. A 12 months post-discharge ICU COVID-19 survivors showed a significant improvement in their nutritional and funcional status, as well as their HRQoL.
One-year post-discharge healthcare resources utilisation of critically ill COVID-19 survivors from NUTRICOVID study
This work aimed to describe the HRU of COVID-19 ICU survivors from the NUTRICOVID cohort for one year after discharge.
Análisis de los costes asociados al seguimiento de pacientes con VIH que discontinúan el tratamiento antirretroviral por falta de eficacia o toxicidad inaceptable en España
Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain compared to the costs involved in the routine follow-up of patients on antiretroviral treatment.
Impact of COVID-19 in nutritional and functional status of survivors admitted in intensive care units during the first outbreak. Preliminary results of the NUTRICOVID study
Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
Cost-effectiveness of Bezlotoxumab for the prevention of recurrence of clostridium difficile infection in high risk patients in Spain
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
